Sermorelin Lab Monitoring: Blood Work Guide | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Sermorelin lab monitoring

Lab guideLast updated: October 28, 2026

Which blood work to run before, during and after a sermorelin cycle, and what the research can and can't tell you about the results. Sermorelin is the first 29 amino acids of natural GHRH. Small human trials show it can raise IGF-1, but not on every schedule: twice-daily injections did, while a single nightly dose didn't (PMID 1379256, PMID 9005976). Treat this panel as a safety baseline plus a rough check on response.

When to test

1. Baseline (before you start)

MarkerWhy test itStandard range
IGF-1
Insulin-like growth factor 1
Your reference point. In older men, 1 mg twice daily raised IGF-1 within 14 days (PMID 1379256), but 2 mg once nightly for 6 weeks did not (PMID 9005976).Depends on age and sex. Labcorp adult examples: ages 21-25, men 109-353 and women 101-347; ages 41-45, men 84-270 and women 74-239; ages 56-60, men 68-247 and women 60-207 ng/mL
Source: Labcorp test 010363
Fasting glucose
Fasting plasma glucose
Growth hormone works against insulin (PMID 29025199), so you want your starting glucose before you push the GH axis. Fast for at least 8 hours before the draw.Normal under 100; prediabetes 100-125; diabetes 126 or higher mg/dL
Source: American Diabetes Association
HbA1c
Hemoglobin A1c
A one-off screen for existing blood-sugar problems. It reflects roughly the last 3 months, so fasting glucose is the marker to repeat during a cycle.Normal under 5.7%; prediabetes 5.7-6.4%; diabetes 6.5% or higher
Source: American Diabetes Association
CBC
Complete blood count
A standard safety baseline before any injectable peptide. Twice-daily sermorelin for 14 days did not change chemistry or hematology profiles in older men (PMID 1379256).WBC 4.0-10 k/mcL; hemoglobin 13-17 g/dL men, 11.5-15.5 g/dL women; platelets 150-400 k/mcL
Source: Cleveland Clinic

2. Mid-cycle (week 4)

IGF-1 may rise, but no rise is common on once-nightly dosing

MarkerWhy test it
IGF-1
Insulin-like growth factor 1
Compare with your baseline, same lab, drawn in the morning before any dose.
Fasting glucose
Fasting plasma glucose
The timely check on blood sugar. Same fasting conditions as baseline.

3. Post-cycle (2-4 weeks after your last dose)

MarkerWhy test it
IGF-1
Insulin-like growth factor 1
Should be back near your baseline.
Fasting glucose
Fasting plasma glucose
Confirms glucose is back where it started.

Ranges differ between labs. IGF-1 ranges also depend on age, sex and the assay the lab uses, so run every IGF-1 draw at the same lab and read it against the age band printed on your own report. Glucose and HbA1c cut-offs are the American Diabetes Association's diagnostic thresholds. CBC ranges come from Cleveland Clinic.

What to expect

  • IGF-1: may rise; not guaranteed (baseline to week 4)

    In 10 healthy men aged about 68, 1 mg twice daily for 14 days raised IGF-1 significantly; the lower 0.5 mg twice-daily dose did not reach significance (PMID 1379256). In 11 men aged 64-76, 2 mg once nightly for 6 weeks nearly doubled night-time GH release with no change in IGF-1 (PMID 9005976). The commonly reported community dose of 200-300 mcg nightly is well below both.

    If it doesn't: There is no established target. A flat IGF-1 on once-nightly dosing matches the research, so IGF-1 can't vouch for your vial. Check the certificate of analysis for your batch.

  • Fasting glucose: may drift up; should stay in range (baseline, week 4, post-cycle)

    Growth hormone raises blood sugar by working against insulin (PMID 29025199). In the sermorelin trials, fasting glucose did not change on twice-daily dosing (PMID 1379256), and glucose and insulin responses to a glucose drink did not change on nightly dosing (PMID 9005976).

    If it doesn't: A move from normal into the prediabetes range (100 or higher) is a reason to stop and talk to a clinician, whatever the source of the vial.

Your labs can't check your vial

Your labs can't check your vial, and with no reliable IGF-1 response at common doses, IGF-1 can't even hint. No peer-reviewed study has tested grey-market sermorelin for identity or purity. FDA has not named sermorelin in its compounding safety review. Identity and purity get checked on the product's certificate of analysis, against the testing lab's own record.

Verify a lab certificate on ThirdPartyVerified →

What the research doesn't show

  • The human trials are small: 10 older men for 14 days at each dose (PMID 1379256) and 11 older men for 6 weeks (PMID 9005976). No trial has tested a 3-6 month cycle at community doses.
  • A 16-week study often cited for sermorelin used a different molecule, [Nle27]GHRH(1-29) (PMID 9141536), so it isn't used here.
  • No sermorelin trial has measured HbA1c. It is on the baseline panel as a general screen, not because sermorelin is known to change it.
  • Banned in sport: the 2026 WADA Prohibited List names sermorelin as a GHRH analogue under S2, prohibited at all times.

Sources

  1. Corpas E, et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992. PMID 1379256
  2. Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997. PMID 9005976
  3. Khorram O, et al. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997. PMID 9141536
  4. Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab 2017. PMID 29025199
  5. Labcorp test 010363: Insulin-like growth factor 1 (IGF-1), age- and sex-specific reference ranges
  6. American Diabetes Association: Diagnosis (A1C and fasting plasma glucose thresholds)
  7. Cleveland Clinic: Complete blood count (normal values for adults)
  8. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (sermorelin not named)
  9. German Sport University Cologne (WADA-accredited lab): S2 Peptide hormones, growth factors, related substances and mimetics (2026 Prohibited List)

Educational content, not medical advice. Reference ranges differ by lab, so read your results against the range printed on your own report, and have a clinician review anything out of range.